Biotech in 2025: A Retrospective
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
Q3 Results Today Live: M&M, Divi’s Lab, Ashok Leyland, Lenskart, LG Electronics, Godrej, Patanjali Foods, AstraZeneca to Announce Q3 Results, Titan, Apollo Hospitals, Britannia Shares Gain, P N Gadgil & Grasim Shares in Red
AstraZeneca CEO Hails NHS Drug Price Deal but Keeps Pause on £200m UK Investment
AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
EU Starts Review of First-Line Enhertu for Breast Cancer
The Top 10 PharmTech Videos of 2025
Proteasomes: A Novel Approach to Target the Immune System
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight
Rethinking Vaccine Production Platforms for Future Pandemics
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
New York Sues Ex-Emergent CEO over Insider Trading During Vaccine Manufacturing Struggle
Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences
AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Product Launches
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
AstraZeneca Bets on In-House AI to Speed up Oncology Research
Women in STEM: Inspiration From Innovators in Pharma
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
Former Emergent CEO Hit With Insider Trading Lawsuit
Twenty-Two Genes Could Hike Risk for Long-Term Health Issues After Epstein-Barr Infection
Eikon Prices Its IPO, Seeking to Raise $318m
White House’s Online Service for Drug Sales Debuts with Limited Impact on Prices
Eikon, a High-Profile Startup Led by Merck Vets, Seeks an IPO
JPM: Illumina Launches 'Unprecedented' Disease Biology Atlas
Is AstraZeneca on Track to Meet Its $80B Revenue Target?
Camizestrant
Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup
U.S. Vaccine Approvals to Undergo Overhaul: What Do the Changes Mean?
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
Targeted Therapy Shows Promise Against Aggressive Brain Tumors
AstraZeneca Gets CRL for Prefilled Pen Version of Lupus Drug Saphnelo
Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
Zoliflodacin (ETX-0914)
Cassidy Bio Closes $8M in Seed Funding
Takeda, Iambic Partner in Latest Pharma AI Push
Eight of the Biggest Immunology and Inflammation (I&I) Deals in 2025
A Clearer Path to Relief: Sinusitis Treatments on the Way
FDA Seeks Changes to GLP-1, Flu Shot Labels
AstraZeneca Pays $630m to Get Full Control of AbelZeta CAR-T
Raised Ties Reaffirm Strategic Trust
Is AstraZeneca’s Surovatamig Underappreciated?
AstraZeneca Ends Work on Cardio Drug; Lisata and Qilu Terminate Deal
AstraZeneca Begins Trading on the New York Stock Exchange